Being tested in large, multicenter trial in ALS patients after pilot trial showed promise. Results are expected late this year. Neurontin isn't FDA-approved for ALS, but doctors can prescribe it, since it's on the market. Parke-Davis has a patient assistance program to help find financial assistance for Neurontin. Being tested in small clinical trial.
Enrollment is complete.
Some results expected in July. This is another strategy to block excess glutamate. Little data available at present.